ReviewExpert review of anti-infective therapy2014
Clostridium difficile infection: molecular pathogenesis and novel therapeutics.
Review in Expert review of anti-infective therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07221370 (Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients), which is not on this map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
Who cites it
64 citing papers in PubMed, 104 citations in OpenAlex.
- Intestinal Microbiome Changes in Fecal Microbiota Transplant (FMT)Canadian journal of gastroenterology & hepatology · 2019Trial
- Trial
- Predictors of RecurrentDiagnostics (Basel, Switzerland) · 2026Article
- Enteric Infections, Dysbiosis, and Metabolic Dysfunction: The Role of Diarrheagenic Pathogens in Insulin Resistance.International journal of molecular sciences · 2026Review
- Metabolic plasticity enables Clostridioides difficile growth in coculture with neutrophils and other mammalian cells.Anaerobe · 2025Article
- Extraintestinal Manifestations ofAntibiotics (Basel, Switzerland) · 2025Review
- CONCURRENTActa clinica Croatica · 2025Article
- Predicting positiveHeliyon · 2025Article
- Unraveling Cecal Alterations inJournal of proteome research · 2024Article
- Best Practices in the Management ofTropical medicine and infectious disease · 2024Review
- Rational Design of Live Biotherapeutic Products for the Prevention ofbioRxiv : the preprint server for biology · 2024Article
- Testing and Diagnosis of Clostridioides difficile Infection in Special Scenarios: A Systematic Review.Cureus · 2024Review
- In Vitro Models for Investigating Intestinal Host-Pathogen Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Reservoirs of Nosocomial Pathogens in Intensive Care Units: A Systematic Review.Environmental health insights · 2024Review
- A Novel Prophage-like Insertion Element withinViruses · 2023Article
- Correlating Antibiotic-Induced Dysbiosis toACS infectious diseases · 2023Article
- Overview of current detection methods and microRNA potential inWorld journal of gastroenterology · 2023Review
- AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge.Gene therapy · 2023Article
- Molecular epidemiology of community- and hospital-associated Clostridioides difficile infections in Jönköping, Sweden, October 2017 - March 2018.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2022Article
- Multimodal Imaging Mass Spectrometry of Murine Gastrointestinal Tract with Retained Luminal Content.Journal of the American Society for Mass Spectrometry · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
The Gram-positive anaerobic bacterium Clostridium difficile produces toxins A and B, which can cause a spectrum of diseases from pseudomembranous colitis to C. difficile-associated diarrhea. A limited number of C. difficile strains also produce a binary toxin that exhibits ADP ribosyltransferase activity. Here, the structure and the mechanism of action of these toxins as well as their role in disease are reviewed. Nosocomial C. difficile infection is often contracted in hospital when patients treated with antibiotics suffer a disturbance in normal gut microflora. C. difficile spores can persist on dry, inanimate surface for months. Metronidazole and oral vancomycin are clinically used for treatment of C. difficile infection but clinical failure and concern about promotion of resistance are motivating the search for novel non-antibiotic therapeutics. Methods for controlling both toxins and spores, replacing gut microflora by probiotics or fecal transplant, and killing bacteria in the anaerobic gut by photodynamic therapy are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.